Tag Archives: Zytiga

New Prostate Cancer Agent Improves Survival by Nearly 5 Months!

Excellent news for prostate cancer patients whose cancer has progressed after hormonal treatment and chemotherapy!   An experimental oral agent, MDV3100 (Medivation) was found to improve survival in metastatic castration-resistant prostate cancer by 4.8 months The new agent, called MDV3100, is … Continue reading

Posted in Cancer, Prostate cancer | Tagged , , , , , , , , , , , , , , , , , | Comments Off on New Prostate Cancer Agent Improves Survival by Nearly 5 Months!

A New Agent That Might Change the Lives of Many Cancer Patients

This is not only good news for all prostate cancer patients, but is also good news for all cancer patients. The investigational radiopharmaceutical radium-223 chloride (Alpharadin) has recently been shown to improve survival in patients with advanced prostate cancer and … Continue reading

Posted in Anal Cancer, Bladder Cancer, Breast cancer, Cancer, Colorectal cancer, Endometrial Cancer, Esophageal Cancer, Gallbladder cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Melanoma, Nasopharyngeal Cancer, Non Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate cancer, Renal Cancer, Small Cell Lung Cancer, Thyroid Cancer | Tagged , , , , , , , , , , , , , , , , , | Comments Off on A New Agent That Might Change the Lives of Many Cancer Patients

New Prostate Cancer Drug Approved by FDA

Good news for patients with metastatic prostate cancer.  The FDA (US Food and Drug Administration) has approved Johnson & Johnson’s Zytiga (abiraterone) in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy.  Abiraterone … Continue reading

Posted in Cancer, Prostate cancer | Tagged , , , , , , , , , | 1 Comment